Items Tagged ‘Hodgkin’s Lymphoma’

December 1st, 2016

Duration of Blood Storage Does Not Affect Outcomes for Patients Requiring Blood Transfusions

By

The length of time that blood is stored prior to a blood transfusion, within normal ranges, does not appear to affect mortality among patients requiring transfusions. These results were recently published in the New England Journal of Medicine. Many patients with cancer require red blood cell transfusions, either in response to the disease itself, or […]

View full entry

Tags: Blood transfusions, Hodgkin's Lymphoma, Leukemia, long-term, Multiple Myeloma, Myeloproliferative Neoplasms MPN, News, Non-Hodgkin's Lymphoma, short-term, storage


June 20th, 2016

CAR Therapy Effective in Advanced Lymphoma

By

According to results of several presentations at the 2016 annual meeting of the American Society of Clinical Oncology (ASCO), chimeric antigen receptor (CAR) therapies appear to have significant anti-cancer activity among patients with different types of lymphomas. This type of treatment is continuing to produce impressive results, and is demonstrating effectiveness in several different types […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Aggressive/Intermediate Grade Non-Hodgkin's Lymphoma, asco, CAR, CAR T, chimeric antigen receptor, Follicular Lymphoma, Highly Aggressive/High Grade Non-Hodgkin's Lymphoma, Hodgkin's Lymphoma, Leukemia, Lymphoma, Mantle Cell Non-Hodgkin's Lymphoma


March 30th, 2016

Defitelio® Approved for Life-Threatening Complication of Stem Cell Transplant

By

The United States Food and Drug Administration (FDA) has approved Defitelio® (defibrotide sodium) for the treatment of hepatic veno-occlusive disease (VOD) following a stem cell transplant. Defitelio is the first approved treatment for severe hepatic VOD. Hepatic VOD is a rare, but life-threatening complication that can occur following chemotherapy and a stem cell transplant (SCT) […]

View full entry

Tags: Chemotherapy, chemotherpay, hepatic VOC, Hodgkin's Lymphoma, HSCT, Leukemia, Lymphoma, Multiple Myeloma, News, Non-Hodgkin's Lymphoma, Stem Cell Transplant


March 14th, 2016

Radiotherapy for Prostate Cancer Increases Risk of Secondary Cancers

By

Patients with prostate cancer considering radiation therapy should now be informed that radiotherapy raises the risk of developing a secondary cancer. Prostate cancer patients who undergo radiotherapy raise their risk of getting other cancers by nearly 70 percent, according to the results of a new study. There is a well-documented association between exposure to radiation […]

View full entry

Tags: Bladder Cancer, bowel cancer, carcinogenesis, Colon Cancer, exposure, Hodgkin's Lymphoma, News, Prostate Cancer, radiation therapy, Rectal Cancer, secondary cancer


October 6th, 2015

ADCETRIS® Provides High-Activity as Initial Therapy in Elderly with Hodgkin’s Lymphoma

By

The agent, ADCETRIS® (brentuximab vedotin), provides high anti-cancer activity as initial therapy in elderly patients who might not be able to tolerate standard therapy for treatment of Hodgkin’s lymphoma. These results were recently published in the journal Blood. Hodgkin’s lymphoma is a type of cancer of the immune system. Standard therapy for Hodgkin’s often includes […]

View full entry

Tags: adcetris, brentuximab vedotin, CD30., Hodgkin's Lymphoma, MMAE, News, Progressive Relapsed Hodgkin's Lymphoma


May 7th, 2015

Adcetris® after Stem Cell Transplant Improves Survival in Hodgkin’s Lymphoma

By

For patients with relapsed or refractory Hodgkin’s lymphoma (HL), treatment with Adcetris® (brentuximab vedotin) after autologous stem cell transplant may improve survival. The Lancet published these findings online. Hodgkin’s lymphoma is a cancer of the lymph system. It typically begins in the lymph nodes in one region of the body and then spreads throughout the […]

View full entry

Tags: adcetris, Autologous Stem Cell Transplant, brentuximab vedotin, HL, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma, refractory, relapsed


December 23rd, 2014

Keytruda PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researchers at the American Society of Hematology (ASH) 56th Annual Meeting, PD-1 blockade has demonstrated efficacy in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, hodgkin's disease, Hodgkin's Lymphoma, keytruda, Lymphoma, News, pembrolizumab, Progressive Relapsed Hodgkin's Lymphoma


December 18th, 2014

PD-1 Immunotherapy Shows Promise in Hodgkin’s Lymphoma

By

The cancer immunotherapy strategy known as programmed cell death 1 (PD-1) has generated great excitement for its ability to help the immune system recognize and attack cancer. Now according to researcher recently published in The New England Journal of Medicine, PD-1 blockade has demonstrated effectiveness in patients with Hodgkin lymphoma (HL). Hodgkin’s lymphoma is a […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, HD, HL, Hodgkin's Lymphoma, Lymphoma, News, nivolumab, PD-1, Progressive Relapsed Hodgkin's Lymphoma


December 12th, 2014

Post-Transplant Adcetris® Improves Treatment of Hodgkin’s Lymphoma and is Likely to Become New Standard of Care

By

The use of post stem cell transplant (SCT) maintenance therapy with Adcetris® (brentuximab vedotin) significantly improved progression-free survival in Hodgkin’s Lymphoma (HL) according to the results of a clinical trail presented at the 56th American Hematological Society Annual Meeting and Exposition, December 6–9, 2014, in San Francisco, California. Hodgkin’s lymphoma is a cancer of the […]

View full entry

Tags: adcetris, Advanced Stage Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, HL, hodgkin lymphoma, Hodgkin's Lymphoma, News, sct


October 30th, 2014

Radiation Therapy Improves 10-Year Survival for Patients With Early Hodgkin’s Lymphoma

By

According to a large observational study based on the National Cancer Database (NCDB), adding consolidation radiation therapy to chemotherapy significantly improves 10-year survival in patients with stage I and II Hodgkin’s lymphoma (HL).  The findings were presented at the American Society for Radiation Oncology’s 56th Annual Meeting in San Francisco. (1) Hodgkin’s lymphoma is a […]

View full entry

Tags: Early Stage Hodgkin's Lymphoma, HD, HL, hodgkin's disease, Hodgkin's Lymphoma, Lymphoma, News, radiation


February 26th, 2014

Rituxan Active in Nodular Lymphocyte-Predominant Hodgkin’s Lymphoma

By

Rituxan® (rituximab) was active in previously treated and untreated patients with nodular lymphocyte–predominant Hodgkin lymphoma, according to the results of a phase II study published in the Journal of Clinical Oncology. Most patients relapsed, but durable response was observed in a substantial minority. Hodgkin’s lymphoma is a cancer of the lymph system and typically begins in […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Early Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News


January 16th, 2014

Adcetris and PET-Adapted Salvage Therapy Effective in Relapsed/Refractory Hodgkin’s Lymphoma

By

Patients with relapsed/refractory Hodgkin’s lymphoma who achieve complete responses after treatment with Adcetris® (brentuximab vedotin) can skip more toxic salvage therapy and proceed straight to transplant, according to the results of a study presented at the 2013 International Symposium on Hodgkin Lymphoma in Cologne, Germany. Hodgkin’s lymphoma is a cancer of the lymph system. It […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma


January 14th, 2014

Adcetris Improves Response Rates to ABVD in Hodgkin’s Lymphoma

By

Adding Adcetris® (brentuximab vedotin) to the chemotherapy regimen ABVD produces a high complete response rate with a moderate increase in toxicity in patients with advanced Hodgkin’s lymphoma, according to the results of a study presented at the 19th International Symposium on Hodgkin Lymphoma held in Cologne, Germany in 2014. Hodgkin’s lymphoma is a cancer of […]

View full entry

Tags: Advanced Stage Hodgkin's Lymphoma, Hodgkin's Lymphoma, News, Progressive Relapsed Hodgkin's Lymphoma


September 16th, 2013

End-of-Life Care Remains Aggressive, Despite Patient Wishes

By

Although most patients with advanced cancer prefer hospice or palliative care that minimizes symptoms, many continue to receive aggressive treatment during their final weeks and months of life. In fact, elderly patients with advanced cancer often receive intensive treatment until the last month of life and hospice care is often delayed until the final three […]

View full entry

Tags: All Cancer Types, Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, Head and Neck Cancer, HIV Related Cancers


May 15th, 2013

Following Lifestyle Recommendations Reduces Risk of Cancer Death

By

People who follow the diet and lifestyle recommendations laid out by the World Cancer Research Fund (WCRF) and the American Institute for Cancer Research (AICR) have a 34 percent reduced risk of dying from several diseases and specifically, a 20 percent reduced risk of dying from cancer compared to people who don’t follow the recommendations, […]

View full entry

Tags: Anal Cancer, Bladder Cancer, Bone Cancer, Brain Cancer, Breast Cancer, Cervical Cancer, Colon Cancer, Esophageal Cancer, Gastric Cancer, General, Head and Neck Cancer, HIV Related Cancers